Branebrutinib clinical trials
Also written BMS-986195.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses branebrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses branebrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedPhase 2Bristol-Myers SquibbNCT04186871Written as branebrutinib
- A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic DermatitisCompletedPhase 2Bristol-Myers SquibbNCT05014438Written as Branebrutinib
- A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05303220Written as Branebrutinib
- Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04515628Written as Branebrutinib
- The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female PatientsCompletedPhase 1Bristol-Myers SquibbNCT03262740Written as BMS-986195
- Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02705989Written as BMS-986195
- A Study of BMS-986195 in Healthy Male SubjectsCompletedPhase 1Bristol-Myers SquibbNCT03245515Written as BMS-986195
Given beside what is tested · 1 — branebrutinib is usual care or a partner of the new treatment
Codes
What other systems call branebrutinib · ClinicalTrials.gg INT001426
- MeSH (NLM) C000710709branebrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 7LBRZUYSHUBRANEBRUTINIBConfirmed FDA, NLM
- NCI Thesaurus C167033BranebrutinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710709 | branebrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 7LBRZUYSHU | BRANEBRUTINIB | Confirmed FDA, NLM |
| NCI Thesaurus | C167033 | Branebrutinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.